{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:26:22Z","timestamp":1773383182607,"version":"3.50.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2020.00413","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T12:27:31Z","timestamp":1589372851000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Cannabinoid as Beneficial Replacement Therapy for Psychotropics to Treat Neuropsychiatric Symptoms in Severe Alzheimer\u2019s Dementia: A Clinical Case Report"],"prefix":"10.3389","volume":"11","author":[{"given":"Michaela","family":"Defrancesco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"B1","volume-title":"Global action plan on the public health response to dementia 2017\u20132025.","year":"2017"},{"key":"B2","volume-title":"World Alzheimer Report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends.","author":"Prince","year":"2015"},{"key":"B3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/PL00014168","article-title":"Neuropathology of Alzheimer\u2019s disease: what is new since A. Alzheimer","volume":"249","author":"Braak","year":"1999","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1042\/CS20100094","article-title":"The vascular contribution to Alzheimer\u2019s disease","volume":"119","author":"Altman","year":"2010","journal-title":"Clin Sci (Lond)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-019-03840-4","article-title":"Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer\u2019s disease patients: a retrospective observational study","volume":"40","author":"Scaricamazza","year":"2019","journal-title":"Neurol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-190662","article-title":"Specific Neuropsychiatric Symptoms Are Associated with Faster Progression in Alzheimer\u2019s Disease: Results of the Prospective Dementia Registry (PRODEM-Austria)","volume":"73","author":"Defrancesco","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jocn.13266","article-title":"Training programmes for family caregivers of people with dementia living at home: integrative review","volume":"25","author":"Sousa","year":"2016","journal-title":"J Clin Nurs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-308112","article-title":"Pharmacological treatment of neuropsychiatric symptoms in Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"86","author":"Wang","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007726.pub3","article-title":"Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia","volume":"3","author":"Van Leeuwen","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2012.11.022","article-title":"Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms","volume":"22","author":"Woodward","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D","article-title":"Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer\u2019s disease","volume":"12","author":"Volicer","year":"1997","journal-title":"Int J Geriatr Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0343-1","article-title":"Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia","volume":"185","author":"Walther","year":"2006","journal-title":"Psychopharmacol (Berl)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001675","article-title":"Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial","volume":"84","author":"van den Elsen","year":"2015","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160533","article-title":"Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model","volume":"54","author":"Aso","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.5_Suppl_6.10S","article-title":"The Neuropsychiatric Inventory: assessing psychopathology in dementia patients","volume":"48","author":"Cummings","year":"1997","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pbb.2019.03.006","article-title":"Cannabinoids, interoception, and anxiety","volume":"180","author":"Andrade","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2009_16","article-title":"Cannabinoids and anxiety","volume":"2","author":"Moreira","year":"2010","journal-title":"Curr Top Behav Neurosci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.05.002","article-title":"Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer\u2019s Disease","volume":"27","author":"Herrmann","year":"2019","journal-title":"Am J Geriatr Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2020.00413\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T12:27:33Z","timestamp":1589372853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2020.00413\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":19,"alternative-id":["10.3389\/fpsyt.2020.00413"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2020.00413","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,13]]},"article-number":"413"}}